ParkerVision permits resale of up to 1.58M shares

Cash exercise of the warrants could provide ParkerVision with up to $526,315 in gross proceeds for general working capital, including litigation expenses.

Rhea-AI Filing Summary

ParkerVision, Inc. (PRKR) has a prospectus permitting the selling stockholder to resell up to 1,578,946 shares of common stock, comprising 1,052,631 shares of common stock and 526,315 shares underlying warrants. ParkerVision will not receive proceeds from resales. To the extent the warrants are exercised for cash, ParkerVision will receive up to $526,315 in gross proceeds, which it expects to use for general working capital, including litigation expenses.

ParkerVision also reported that the Court of Appeals for the Federal Circuit issued its order in the expedited appeal of the company’s patent infringement case against Qualcomm. The company stated that its Form 424B3 updates typically do not involve the issuance of new securities.

Key Figures

Shares permitted for resale: Up to 1,578,946 shares of common stock Common stock shares: 1,052,631 shares Shares underlying warrants: 526,315 shares +1 more

4 metrics

Shares permitted for resale Up to 1,578,946 shares of common stock Under the prospectus

Common stock shares 1,052,631 shares Part of the shares permitted for resale

Shares underlying warrants 526,315 shares Part of the shares permitted for resale

Gross proceeds from cash warrant exercises Up to $526,315 ParkerVision receives proceeds to the extent the warrants are exercised for cash

Key Terms

Warrants, gross proceeds, selling stockholder, incorporated by reference, +1 more

5 terms

Warrants financial

"shares of Common Stock underlying warrants (“Warrants”)"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

gross proceeds financial

"up to an aggregate of $526,315 in gross proceeds"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

selling stockholder financial

"resale by the selling stockholder"

A selling stockholder is an individual or entity that owns shares of a company's stock and chooses to sell some or all of those shares to others. This often occurs when the owner wants to cash in on their investment or reduce their stake. For investors, understanding who the selling stockholder is can provide insights into potential changes in the company's ownership or market activity.

incorporated by reference regulatory

"attached as Exhibit 99.1 and is incorporated herein by reference"

expedited appeal regulatory

"order in the expedited appeal of the Company's patent infringement case"

Offering Details

secondary · Up to 1,578,946 shares of Common Stock

Offering

Offering Type secondary

Securities Offered Common Stock

Offering Amount Up to 1,578,946 shares of Common Stock

Use of Proceeds ParkerVision will not receive proceeds from sales by the selling stockholder. To the extent the Warrants are exercised for cash, ParkerVision will receive up to an aggregate of $526,315 in gross proceeds, which it expects to use for general working capital purposes, including payment of litigation expenses.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PRKR shares can be resold under the prospectus?

The prospectus permits resale of up to 1,578,946 shares of common stock, comprising 1,052,631 shares of common stock and 526,315 shares underlying warrants.

How much can ParkerVision receive from PRKR warrant exercises?

ParkerVision will receive up to $526,315 in gross proceeds to the extent the warrants are exercised for cash. The company expects to use proceeds received, if any, for general working capital, including litigation expenses; it will not receive proceeds from the selling stockholder’s resales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 06:03 PM Accepted by SEC EDGAR 10/01/2026 - 04:03 PM Learn about SEC filing dates

Filed pursuant to Rule 424(b)(3)

Registration No. 333-262147

PROSPECTUS SUPPLEMENT No. 58

(to Prospectus dated January 24, 2022)

PARKERVISION, INC.

1,578,946 Shares of Common Stock

This Prospectus Supplement relates to the prospectus dated January 24, 2022, as amended and supplemented from time to time (the “Prospectus”), which permits the resale by the selling stockholder listed in the Prospectus of up to 1,578,946 shares of our common stock, par value $0.01 per share (“Common Stock”) consisting of an aggregate of 1,052,631 shares of Common Stock and 526,315 shares of Common Stock underlying warrants (“Warrants”) issued pursuant to a securities purchase agreement dated December 14, 2021.

We will not receive proceeds from the sale of the shares of Common Stock by the selling stockholder. To the extent the Warrants are exercised for cash, we will receive up to an aggregate of $526,315 in gross proceeds.  We expect to use the proceeds received from the exercise of the Warrants, if any, for general working capital purposes, including payment of litigation expenses.

This Prospectus Supplement is being filed to update and supplement the information previously included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on October 1, 2026.  Accordingly, we have attached the 8-K to this prospectus supplement.  You should read this prospectus supplement together with the prospectus, which is to be delivered with this prospectus supplement.

Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that information in this Prospectus Supplement modifies or supersedes such statement.  Any statement that is modified or superseded shall not be deemed to constitute a part of the Prospectus except as modified or superseded by this Prospectus Supplement. 

This Prospectus Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus.

Our Common Stock is listed on the OTCQB Venture Capital Market under the ticker symbol “PRKR.”

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 5 of the Prospectus for a discussion of information that should be considered in connection with an investment in our securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined whether this Prospectus or Prospectus Supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this Prospectus Supplement is October 1, 2026.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 1, 2026

PARKERVISION, INC.

(Exact Name of Registrant as Specified in Charter)

Florida	000-22904	59-2971472
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4446-1A Hendricks Avenue Suite 354, Jacksonville, Florida	32207
(Address of Principal Executive Offices)	(Zip Code)

(904) 732-6100

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Item 8.01 Other Events

On October 1, 2026,  ParkerVision, Inc. (the “Company”) issued a press release announcing that the Court of Appeals for the Federal Circuit issued its order in the expedited appeal of the Company's patent infringement case against Qualcomm.  A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K, including Exhibit 99.1 hereto, has been “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section. The information in this Current Report shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

The Company will file prospectus supplements on Form 424B3 to update previously filed S-1 registration statements to maintain their effectiveness.  These Form 424B3 filings typically follow the filing of the Company's periodic reports with the SEC, including Forms 8-K, and do not involve the issuance of any new securities by the Company.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit	Description
99.1	Press Release
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 1, 2026

PARKERVISION, INC.

By /s/ Cynthia French

Cynthia French

Chief Financial Officer